Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial.
Authors: Giordano FA; Department of Radiation Oncology, Medical Faculty Mannheim, University Medicine Mannheim, Heidelberg University, Mannheim, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; Mannheim Institute for Intelligent Systems in Medicine, Medical Faculty, Heidelberg University, Mannheim, Germany. Electronic address: frank.giordano@umm.de., Ganslandt O; Department of Neurosurgery, Medical Center Stuttgart, Stuttgart, Germany., Münter MW; Department of Radiation Oncology, Medical Center Stuttgart, Stuttgart, Germany., Combs SE; Department of Radiation Oncology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany; Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany; Deutsches Konsortium für Translationale Krebsforschung, Partner Site Munich, Munich, Germany., Diehl C; Department of Radiation Oncology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany; Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany; Deutsches Konsortium für Translationale Krebsforschung, Partner Site Munich, Munich, Germany., Meyer B; Department of Neurosurgery, Technical University of Munich, Munich, Germany., Herrlinger U; Department of Neurooncology, Center for Neurology and Integrated Oncology, University Hospital Bonn, Bonn, Germany., Schneider M; Department of Neurosurgery, University Hospital Bonn, Bonn, Germany., Kahl KH; Department of Radiation Oncology, University Medical Center Augsburg, Augsburg, Germany., Shiban E; Department of Neurosurgery, Medical University Lausitz-Carl Thiem, Cottbus, Germany., Goenka A; Department of Radiation Medicine, Northwell, Zucker School of Medicine at Hofstra Northwell, Lake Success, New York, NY, USA., Schulder M; Department of Neurosurgery, Northwell, Zucker School of Medicine at Hofstra Northwell, Lake Success, New York, NY, USA., Lucas A; Department of Radiation Oncology, Institut Català d'Oncologia, L'Hospitalet, Barcelona, Spain., Plans G; Department of Neurosurgery, Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain., Brehmer S; Department of Neurosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Ruder AM; Department of Radiation Oncology, Medical Faculty Mannheim, University Medicine Mannheim, Heidelberg University, Mannheim, Germany., García-Cabezas S; Department of Radiation Oncology, Reina Sofia University Hospital, Instituto Maimónides de Investigaciones Biomédicas de Córdoba, Córdoba, Spain., Solivera J; Department of Neurosurgery, Reina Sofia University Hospital, Instituto Maimónides de Investigaciones Biomédicas de Córdoba, Córdoba, Spain., Cifarelli CP; Department of Neurosurgery, West Virginia University, Morgantown, West Virginia, USA., Wenz F; Freiburg University Medical Center, University of Freiburg, Freiburg, Germany., Sarria GR; Department of Radiation Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany., Pope WB; UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Layer JP; Department of Radiation Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany; Institute of Experimental Oncology, Medical Faculty, University Hospital Bonn, University of Bonn, Bonn, Germany., Tsien CI; Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada., Petrecca K; Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Corporate Authors: INTRAGO-II Study Group
Source: The Lancet. Oncology [Lancet Oncol] 2026 Jul; Vol. 27 (7), pp. 864-878.
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(26)00235-4